Ventilator Associated Pneumonia ( VAP)
20
3
4
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.0%
1 terminated out of 20 trials
91.7%
+5.2% vs benchmark
30%
6 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (20)
Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients
Integrated vs Manual Endotracheal Tube Cuff Pressure Monitoring and Ventilator-Associated Pneumonia
Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia
Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia
Impact of Oral Care on Ventilator Associated Pneumonia
Effect of Implementing Evidence-based Practice and Nurse's Behavior Change on Quality of Care in Intensive Care Unit: Focus on Ventilator Associated Pneumonia in a Tertiary Hospital in Bangladesh
Effect of Two Oral Care Methods on Oral Flora and VAP in Mechanically Ventilated Patients
Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics in the Diagnosis and Prognosis of VAP
Impact of Antibio Prophylaxis on Occurence of Ventilator Associated Pneumonia in Trauma Patients
VAP Identification by AI
Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-associated Pneumonia in Critically Ill Children
Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella
A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis
Pulmonary Infections and Barotrauma Associated With MV IN PICU
Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients
Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
High Dose of Vitamin C on Mechanically Ventilated Septic Patients in Intensive Care Unit
Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial